Encochleated Amphotericin B
Phase 1/2Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cryptococcal Infections
Conditions
Cryptococcal Infections
Trial Timeline
Oct 1, 2018 → Mar 1, 2020
NCT ID
NCT03196921About Encochleated Amphotericin B
Encochleated Amphotericin B is a phase 1/2 stage product being developed by Matinas Biopharma for Cryptococcal Infections. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03196921. Target conditions include Cryptococcal Infections.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03196921 | Phase 1/2 | Withdrawn |
Competing Products
18 competing products in Cryptococcal Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine | Novartis | Phase 2 | 52 |
| Mycograb + placebo | Novartis | Phase 2 | 52 |
| Single dose liposomal Amphotericin and Fluconazole + Fluconazole | Gilead Sciences | Phase 2/3 | 64 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Phase 3 | 76 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Lobradimil + Amphotericin B | Alkermes | Phase 1 | 30 |
| Flucytosine and fluconazole + Fluconazole | Bausch Health | Phase 2 | 47 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 3 | 69 |